CG Oncology, Inc. Common stock earnings per share and revenue
On Nov 14, 2025, CGON reported earnings of -0.56 USD per share (EPS) for Q3 25, beating the estimate of -0.57 USD, resulting in a 0.21% surprise. Revenue reached 1.67 million, compared to an expected 66.61 thousand, with a 2401.28% difference. The market reacted with a +8.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.62 USD, with revenue projected to reach 484.50 thousand USD, implying an increase of 10.71% EPS, and decrease of -70.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were CG Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, CG Oncology, Inc. Common stock reported EPS of -$0.56, missing estimates by 0.21%, and revenue of $1.67M, 2401.28% above expectations.
How did the market react to CG Oncology, Inc. Common stock's Q3 2025 earnings?
The stock price moved up 8.61%, changed from $37.76 before the earnings release to $41.01 the day after.
When is CG Oncology, Inc. Common stock expected to report next?
The next earning report is scheduled for Mar 26, 2026.
What are the forecasts for CG Oncology, Inc. Common stock's next earnings report?
Based on 17
analysts, CG Oncology, Inc. Common stock is expected to report EPS of -$0.62 and revenue of $484.50K for Q4 2025.